Shares of ImmunoCellular Therapeutics (OTC: IMUC) staged a huge rally in today’s over-the-counter market. The small cap stock closed today’s trading session at $3.71 or 13.11% than yesterday’s closing price, with volume up from daily average of 386,695 to 1.91 million. At one point during the day shares of ImmunoCellular Therapeutics peaked at $4.00, which is also its highest share price year to date.
ImmunoCellular Therapeutics has been experiencing an incredible rally this year, with a 144.78% total gain from the start of 2012. The stock achieved a prior peak of $3.15 on March 13, 2012 and then experienced a volatile period until May 8th, when its stock chart became attractive again. ImmunoCellular Therapeutics has been steadily rallying since that point.
ImmunoCellular shares are soaring which has been linked to the company’s statement today about how it will present new data from the previously-announced Phase I clinical trial of ICT-107. This is the company’s major cancer vaccine cancer treatment candidate for glioblastoma multiforme.
For anyone not familiar with ImmunoCellular Therapeutics, it is an experimental stage biotechnology corporation that focuses on developing innovative immune-based products to diagnose and treat cancer. Their technologies and products are designed to exploit the control of the immune system to facilitate the diagnosis and treatment of cancer. They are developing active immune-therapies that aim at not only ordinary tumor cells, but also the cancer stem cells that are supposed to bring about cancer recurrence and growth.
The company has recently provided an update on the experimental trial site movement as well as the number of patients signing up for its stage II medical test of ICT-107. It is the corporation’s dendritic cell cancer prevention aiming at numerous lump cells in the healing of glioblastoma multiforme. It has also begun the test in 25 sites, with patients signed up in major medical centers. In addition, ImmunoCellular Therapeutics has announced that its ordinary stock has been approved for listing on the New York Stock Exchange where trading is projected to begin on Wednesday, May 30th, 2012 using the symbol ‘IMUC’.
The company is looking forward to commercializing and developing innovative therapeutics to reduce cancer using the immune system. The Company’s most recent actions are concentrated on the experimental use of ICT-107, a cancer immune treatment to treat glioblastomamultiforme. ImmunoCellular Therapeutics is also in the pre-clinical growth stage to develop two extra therapies to treat solid tumor and ovarian cancers.
For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com